1
2017 MEDICINES MONITOR
2017 EDITION
MEDICINES MONITOR
Dutch association
InnovativeMedicines
MEDICINES MONITOR2017 EDITION
Life expectancy in the Netherlands is still on the rise. This is one of the main focuses of ‘A better life’. Currently Dutch men reach an average age of eighty years and women live a few years longer. Around the year 2040 they will even live to be ninety. Medicines make a key contribution to this development. However, alertness is still required. Though it is true that people live longer, they suffer from various chronic diseases increasingly. This calls for an adequate cooperation between health care providers, in order to encourage the correct use of medicines while maintaining manageable costs.
Finally it is interesting to look at the financial revenues of medicines. It is well known that they can prolong life and improve the quality of it. But they also save society hundreds of millions of euros every year. Think of extra labour participation and less sick leave. The infographics in this digital brochure show the relevant figures.
Those who would like to join in the public debate on the future of medicines, are very welcome to do so. Sooner or later, almost every Dutch person will need medicines, so this is a subject that concerns us all. As for every discussion, it is advisable to base opinions on facts as much as possible. This Medicines Monitor provides you with ample starting points.
Gerard SchouwDirector general Association Innovative Medicines
‘Sustainable health care’, ‘Medicines of tomorrow’ and ‘A better life’. These three are the central themes within our industry association for Dutch pharmaceutical companies. We have structured this brochure along those lines. In our annual Medicines Monitor, formerly called Pharma Facts, you will find the relevant recent key figures.Although the clear infographics are mainly self-explanatory, here follows a brief introduction.
Concerning the theme ‘Sustainable health care’, the increase of the number of medicines used in the Netherlands during the past ten years stands out, from a good six billion to over eight billion doses a year. Yet annual medicine turnover has remained at a reasonably constant level over the last decade: at around five billion euros. This means we achieve more with the same amount of money. Still it remains one of our most important challenges to monitor the cost of medicines sharply.
‘Medicines of tomorrow’ highlights a different topic. It shows that over twenty types of cancer are being treated with medicines that have been developed in the course of the last five years. More than seven thousand medicines are under development, of which over 1,800 for cancer. Many of these are new ‘personalised medicines’. It is interesting that also in the Netherlands, 600 applications for clinical research are submitted every year, approximately two thirds of those applications are filed by pharmaceutical companies. Innovation is clearly very much on the agenda, and this is good news for numerous patients and their families.
PREFACE
76
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
6
A BETTER LIFEMedicines are indispensable for the daily life of a huge number of people. The proper deployment of the right medicine enables them to live a longer and healthier life. It gives them back their freedom, allows them to return to work sooner and helps them to ease their pain. There is also a growing interest in preventive medicines, because of which diseases do not even have a chance to occur.
Innovative medicines for cancer have radically changed the lives of millions of people in Europe. Two in three patients diagnosed with cancer, stay alive for at least five years longer thanks to these medicines. The quality of life improves. Also because sometimes there is no more need for chemotherapy, a treatment that often causes serious side effects. The introduction of ‘perso-nalised medicines’ – tailor-made medicines – even offers us the perspective that instead of being the equivalent of a death sentence, cancer will become a chronic condition.
Because of their continuous search for new medicines, pharmaceutical companies have contributed considerably to the lengthening of life expectancy of the Dutch population.
83,182,780,680,179,276,575,372,6
79,778,875,573,872,570,871,470,3
20151950 1960 1970 1980 1990 2000 2010
MEDICINES PROLONG OUR LIVES
Absolute life expectancy, in the Netherlands in years
60
20
80
40
0
100
man woman
Source: Centraal Bureau voor de Statistiek (Statistics Netherlands), 2016
98
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
Major progress is being made in fighting cancer. It is expected that cancer will increasingly be considered a chronic disease, that can be controlled with medicines and treatment.
Source: Centraal Bureau voor de Statistiek (Statistics Netherlands), 2016
Prostate cancer +24%64% 88%
All types of cancer
Percentages of increase in five-year survival rates of various types of cancer1989-1993 compared to 2008-2012
+15%47%
Colon cancer +8%62%54%
Non-small cell lung cancer +3%17%14%
Lung cancer +5%17%12%
Cervical cancer +3%66%63%
Period1989-1993
Period2008-2012
62%
Skin cancer/melanoma +8%81% 89%
Breast cancer +10%77% 87%
Small-cell lung cancer +3%7%4%
INCREASED CANCER SURVIVAL RATES
Source: Farminform, 2017
Doses prescribed (DOT), in billions
5 years or shorter on the market
longer than 5 years on the market
9
0
1
2
3
5
6
7
8
4
10
NEWEST MEDICINES PRESCRIBED RELATIVELY INFREQUENTLY
Dutch doctors take a very careful approach to the prescription of medicines that have recently been brought onto the market. As a result, Dutch patients will have to wait longer before being able to profit from the latest medical discoveries. In other EU-countries, doctors tend to opt for a new branded medicine more easily.
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
5,1%5,6% 6,7%
6,8% 6,9%6,7%
5,5%5,1%
5,8%5,2%
4,2%3,2% 1,9% 1,2%
0,7% 0,7% 0,8% 0,7% 0,7% 0,7% 0,6%
1110
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
The average period of time needed in the Netherlands for a medicine to become available for the patient, is 207 days, as from the moment of marketing authorisation. On average, this should take 90 days at most.
Average time in days between marketing authorisation and availability for the patient.
FROM MARKETING AUTHORISATIONTO AVAILABILITY FOR THE PATIENT
Source: EFPIA, Patient W.A.I.T. Indicator, 2016
1 in 6 Dutch is 65+
POLYPHARMACY IN ELDERLY PEOPLE
Nearly one million elderly people take more than 5 types of medicines every day. This increases the risk of side effects. Close cooperation between health care workers and involvement of the patient are essential in encouraging the correct use of medicine.
16.000Source: RIVM Polyfarmacie bij kwetsbare ouderen (Polypharmacy in vulnerable elderly people), 2013
elderly people end up in hospital as a result of erroneous use every year.
United Kingdom 138
Germany 110
Switzerland 76
Denmark 110
Austria 231
Netherlands 207
Finland 122
Norway 172
Italy 370
France 467
Slovenia 47631%
82%
62%
59%
74%
90%
49%
74%
90%
74%
74%
77%
Sweden 292
% of the 39 EMA-registered medicines available, in 2015
1312
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
88 90
In 2040 men are expected to reach an average age of 88 years while women will reach the age of 90 on average.Source: IFPMA
The number of patients diagnosed with prostate cancer remains more or less constant. However, the number of patients surviving after ten years has increased.
Ten-years prevalence The ten-years prevalence of cancer includes all patients who are still alive at a certain date and who have been diagnosed with a form of cancer in the past ten years.
Incidence The incidence of cancer con-cerns the rate of occurrence of new cases diagnosed in a cer-tain period (usually in 1 year)
numbers in thousands
Source: www.cijfersoverkanker.nl, 2017
Our life expectancy continues to increase
2010 2011 2015 2016*201420132012
50
60
70
80
0
10
20
30
40
* provisional figure
MEN LIVE LONGER WITH PROSTATE CANCERCOMPARED TO THE TOTAL NUMBER OF PATIENTS DIAGNOSED WITH PROSTATE CANCER IN THE PAST 10 YEARS
1514
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
The Netherlands leads the way as far as its reserve towards the use of antibiotics is concerned. Yet we clearly see regional differences in the Netherlands. The development of new antibiotics remains vitally important.
USE OF ANTIBIOTICS IN THE NETHERLANDS IS LOW
Source: OESO Source: OESO
Less than 19%
19 to 21%
21 to 23%
23 to 25%
25% or more
Percentage of the population that was prescribed antibiotics, 2013. (adjusted for age)
15
20
25
30
10
5
0
Daily doses per 1,000 inhabitants
NLD EST SWE LV HUN SVN DEU NOR AUT DNK FIN LTU CZE GBR ISL PRT POL SVK IRL ESP LUX ITA BEL FRA GRC
35
REGIONAL DIFFERENCES IN THE NETHERLANDS
WITHIN EUROPE, FEWEST ANTIBIOTICS PRESCRIBED IN THE NETHERLANDS
1716
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
The number of new patients diagnosed with breast cancer has continued to grow until 2016. However, the number of patients that die of breast cancer remains almost unchanged. Chances of surviving the disease are improving. Earlier diagnostics, more effective treatments and innovative medicines all contribute to this.
CHANCES OF BREAST CANCER SURVIVAL ARE IMPROVING
Source: www.cijfersoverkanker.nl / www.stateline.nl, 2016
Number of new breast cancer patients in the Netherlands per year
Number of patients who die of breast cancer every year
2004 2008 20122006 2010 2014 2015*
* provisional figure
12.140
3.333
12.527
3.350
13.149
3.357
13.402
3.245
14.388
3.230
14.657
3.041 3.294
14.61415.000
13.000
12.000
10.000
11.000
14.000
9.000
8.000
7.000
6.000
3.000
2.000
1.000
5.000
4.000
0
1918
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
18
SUSTAINABLE HEALTH CARE
7% OF ALL EXPECTED PUBLIC HEALTH EXPENDITURE IS SPENT ON EXTRAMURAL MEDICINES
Source: Dutch National Budget VWS (Ministry of Health, Welfare and Sport) for 2017, Prinsjesdag (Dutch Budget day), 2016
7%
32%
27%
7%
27%Long-term care
Hospitals, medical specialists and other curative care
Other
Primary
We have been spending approximately the same amount of money on medicines for years in the Netherlands. Less than 10 percent of our total health care budget has been spent on medicines, around 5 billion euro every year. Due to the fact that our population is ageing budgets are under pressure. New technologies provide us with ever-growing opportunities. Beneficial as this may be for the patient, it will increase the cost of our health care. But it can also lead to savings, for example by means of e-health applications at home.
In the field of medicines, we see an increase in ‘personalised treatments’, through which patients receive real tailor-made care. This type of medicine is often far more effective than the traditional medicines. Furthermore, it can reduce side effects dramatically. The patient profits enormously. But there is a price tag. Particularly because the medicines involved are very complex and entail a complicated and vulnerable production process, mostly for a relatively small patient population.
We all want patients to have and continue to have access to the best medicine available. A medicine that also has been proven to be safe and effective. To achieve this a lot of money is needed. It easily takes 1 to 2 billion euro to develop a new medicine. At the same time, we want our health care to remain affordable. We have no use for new medicines if we don’t have the money to pay for them.
Cooperation between pharmaceutical manufacturers and other health care parties is indispensable in the effort to ensure better health care that is lasting and affordable. This is what we subscribe to.
In 2017, we expect to spend 73.5 billion euro on public health. Of this total, 4.8 billion euro (7%) is spent on medicines prescribed by general practitioners (extramural medicines).
2120
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
In 2015 costs of medicines in hospitals amounted to over 2 billion euro. The total hospital budget is more than 23 billion euro.
Source: CBS (Statistics Netherlands) 2016; Rijksbegroting (Dutch National Budget) 2016; Farminform 2017; IMS (Market prognosis 2015-2019, Netherlands)
MEDICINE COSTS IN HOSPITAL BUDGET ARE LIMITED
Sources: Life Cycle database – IMS Health, April 2015; IMS market segmentation database NL, April 2015; Farminform AIP turnover MAT December 2014. Based on calculations Association Innovative Medicines.
FUNDS AVAILABLE DUE TO PATENT EXPIRATION
With the patents that have expired in 2016 and those that will expire in 2017 and 2018, hundreds of millions of euros can be saved as a result of growing competition. This money can be used to pay for the development of new, innovative medicines.
2014 and 2015 Health care Insurance Act costs, provisional figures CBS (Statistics Netherlands) / 2016 Health care Insurance Act costs from the Rijksbegroting (Dutch National budget) 2017
5
10
15
20
25
0
2000 20092004 20152002 20122006 20112001 20102005 20162003 20142007 20132008
Health care costs in billions €
Health care Insurance Act: hospitals and medical specialists
Prescription medicines Available funds as a result of expired patents: Total Extramural Intramural
€ 0
€ -100.000.000
€ -50.000.000
€ -150.000.000
€ -250.000.000
€ -350.000.000
€ -200.000.000
€ -300.000.000
€ -400.000.000
2016 2017 2018
2322
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
The total turnover on medicines has remained practically constant during the last ten years, around five billion.
TOTAL TURNOVER ON MEDICINES REMAINS CONSTANT
5
Intramural turnover on
medicines in euros
Extramural turnover on
medicines in euros
Total turnover on medicines in billions of eurosAmounts are based on pharmacy purchase prices. The actual market price is the result of negotiations between health care stakeholders.
Source: Farminform, 2017
1996 20052000 2010 2015
3
2
1
4
0
2524
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
turnover total
VOLUME MEDICINES IN THE NETHERLANDS INCREASING
The total number of medicine doses is increasing, up to 9 billion in 2016. This increase is mainly caused by a growing prescription of generics in the Netherlands.
volume total
volume generic
volume branded medicines
Development in billions of standard daily doses Development in billions of euros
Source: Farminform, 2017
TURNOVER MEDICINES CONSTANT
We have been spending around 5 billion euro on medicines for years in the Netherlands. Turnover for generics has increased up to 0.8 billion. Branded medicines show an increase up to 4 billion.
Amounts are based on pharmacy purchase prices. The actual market price is the result of negotiations between health care stakeholders.
Source: Farminform, 2017
2015 20161996 2000 2005 20100
4
2
8
6
10
201620151996 2000 2005 20100
2
1
4
5
3
6
turnover generic
turnover branded medicines
2726
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
Compared to other sectors, such as education, transportation and housing, the price index of medicines has decreased considerably in the last 10 years.
Consumer price index compared to the price index for prescription medicines (1996 = 100)
Source: Stichting Farmaceutische Kerngetallen (Foundation for Pharmaceutical Statistics) 2015, Farminform 2016, CBS (Statistics Netherlands) 2016
Since 1996, various measures and agreements have contributed to the price decrease of medicines.
1. Housing, water and energy2. Transportation3. Total expenditure4. Education5. Food6. Prescription medicines
Total health care expenditure per country as % GDP
HEALTH CARE COSTS IN THE NETHERLANDSACCOUNT FOR 10,8% OF TOTAL EXPENDITURE
We spend a lot of money on good health care in the Netherlands. In 2015 the amount spent added up to about €5,000 per person. When we compare the costs of health care, we are in 7th position, behind countries like Japan, France, Germany and the US.
OECD 2016
PRT
8,9
8,4
302
USA
16,9
12,5
18.0
37
BEL
10,4
7,9
498
SWE
11,1
7,4
458
ESP
9,0
6,8
1.60
3
DEU
11,1
9,8
3.85
7
AUT
10,4
9,2
415
FRA
11,0
9,5
2.64
8
FIN
9,6
6,9
225
NLD
10,8
7,1
818
DNK
10,6
8,1
265
GBR
9,8
6,3
2.70
1
CH
11,5
9,3
506
ITA
9,0
7,6
2.19
1
JPN
11,2
7,4
4.73
8
IRL
9,4
5,9
302
2015 - 10,8%of $ 818 billion GDP
2000 - 7,1%of $ 502 billion GDP
percentage health care 2015 percentage health care 2000 in billion $ 2015 GDP
1
234
5
1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 20160
20
40
60
80
100
120
140
160
180
Introduction Medicines Pricing Act
(WGP)
Clawback Increase
Agreement (VWS-KNMP)
Temporary introduction
measure ‘De Geus’
Transition agreement
Introduction clawback
Start agreement period
(Individual ) Preference policy
Introduction free pricing
DECREASE OF AVERAGE MEDICINE PRICE
6
2928
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
In addition to the direct benefits such as saved costs, the indirect benefits such as extra labour participation and less sick leave, yield an important social benefit.
INNOVATIVE MEDICINES YIELD A LOT OF MONEY
STROKE Stroke-related health care costs decreased
thanks to anti-hypertension medication.
DIABETESSaved health care costs as
a result of less complications thanks to modern
diabetes medicines.
MIGRAINE Less absence thanks
to triptans.
DIABETES Extra labour participation and less sick leave thanks
to modern diabetes medicines.
MULTIPLE SCLEROSIS Lower health care costs, less informal health care and less sick leave as a result of fewer relapses.
RHEUMATISM Less absence thanks
to biologicals.
BREAST CANCER Extra labour supply as a
result of increased survival of breast cancer thanks to better
treatment options.
715 287
115 115
500 100
36
10 12
30
125 42
High variant
Low variant
0,6 - 1,6BILLION EURO BENEFITS
37
5
Source: Marc Pomp, Arbeidsbaten en uitgespaarde zorgkosten door innovatieve geneesmiddelen (Labour benefits and saved health care costs thanks to innovative medicines), 2015
With simple methods and by tearing down health care partitions we will be able to save over 1.5 billion euro on health care costs.
+ €1,5 BILLION
Source: SIRM, 2016
Changing the health care system by tearing down partitions will benefit patients and society
30
MEDICINES MONITOR 2017
It often takes a long time for new extramural medicines to be included in the basic care package. The reimbursement process sometimes takes up to 232 days, where 90 days is the standard.
INCLUSION NEW MEDICINES IN BASIC HEALTH INSURANCE PACKAGE
Source: Zorginstituut Nederland (National Health Care Institute), 2016
900
Standard according to Transparancy
Directive
1
50
153
232
1A-LIST
1B-LIST
The average duration was 64 days, with a varying length, ranging from a minimum of 1 to a maximum of 153 days.
The average duration was 141 dagen, with a varying length, ranging from a minimum of 50 to a maximum of 232 days.
64% 8%14FILES OF DRUGS THAT CAN BE CLUSTERED (1A-LIST), OF WHICH 64% COMPLETED WITHIN THE LEGAL TERM
12FILES OF DRUGS THAT
CANNOT BE CLUSTERED (1B-LIST), OF WHICH 8%
COMPLETED WITHIN THE LEGAL TERM MEDICINES
OF TOMORROWThe development of innovative medicines is accelerating at an unprecedented pace. More than 7,000 new medicines are being developed. Such as ‘personalised’medicines: very effective drugs, tailor-made for small patient populations. We use more and more biologicals, medicines based on natural or human substances. DNA-diagnostics are used more often. Only a few drops of blood suffice to predict future diseases or, preferably, to prevent them. For the most part, these innovations are developed in laboratories of pharmaceutical companies – breeding ground for the medicines of tomorrow. Not only because of spectacular inventions, but also through meticulous testing of promising drugs for safety and effectiveness. A costly process that requires perseverance. But we are beginning to reap the benefits. For this, cooperation between universities, pharmacists and other health care parties is paramount. The Netherlands has the potential to be among the best in the world in the discovery and development of innovative medicines. That is why we should continue to invest in a thriving research climate.
31
3332
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
Medicines have a major impact on many diseases. Thanks to medicines, a large number of HIV-infected patients for example enjoy a reasonably good quality of life, and cancer mortality is decreasing.
MEDICINES ARE AMONG THE MOST POWERFUL FORMS OF CARE IN THE TREATMENT AND CURING OF DISEASES
Source: Health Advances analysis
95%Of the 15 million of hepatitis C patients in Europe 95% can be healed with an 8- to 12-week treatment.
37%From 2000 to 2012 mortality rate for cardiovascular conditions has decreased with 37% in EU5.
94%Since 1991 mortality of HIV-infected patients living in France has decreased with 94% (mortality: age-standardised).
21%Since 1991 mortality rate for all cancer types has decreased with 21%.
MEDICINES WITH NEW ACTIVE INGREDIENT
A growing number of promising medicines with new molecules are being developed.
period 1963-1976 period 1977-1996 period 1997-2016
Number of medicines per year
Average number of medicines per year
per period
15,9
25,2
30,2
Source: DiMasi, Tufts Center for the Study of Drug Development, Tufts University
THAT ARE APPROVED BY THE FDA PER YEAR
FDA = Food and Drug Administration
1990198019701960 2000 2010 2016
1963 1977
1997
0
20
10
30
40
50
60
3534
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
Kidneys • Pancreas • Neutropenia • Castleman disease • Cervix • Myelofibrosis Polycythemia Vera (bone marrow) • Stomach • GIST (rare form of soft tissue sarcoma) • Neuroblastoma
Basal cell carcinoma
Sarcoma (soft tissue)
Bowel
Lungs
Lymph nodes
Leukaemia
Breast
Kahler’s disease
Ovaries
Thyroid
Skin
Prostate
• belinostat (PTCL)• bortezomib (MCL)• brentuximab vedotin (Hodgkin’s,
ALCL)• chidamide (PTCL)• ibrutinib (MCL, WM)• idelalisib (CLL, FL, SLL)• mogamulizumab (ATCL)• pixantrone (NHL)• rituximab (NHL)• romidepsin (PTCL, CTCL)
• ado-trastuzumab emtansine• palbociclib• pertuzumab
• sonidegib• vismodegib
• bevacizumab• olaparib
• regorafenib• tipiracil/trifluridine• ziv-aflibercept
• cobimetinib• dabrafenib• ipilimumab • nivolumab• pembrolizumab• trametinib• talimogene laherparepvec• vemurafenib
• carfilzomib• daratumumab• elotuzumab• lxazomib• panobinostat• pomalidomide
• abiraterone acetate • enzalutamide• ra 223 dichloride
• mifamurtide (osteosarcoma)• trabectedin (liposarcoma or
leiomyosarcoma)
• afatinib• alectinib• ceritinib• crizotinib• gefitinib• nivolumab• necitumumab• osimertinib• pembrolizumab• ramucirumab
• blinatumomab (ALL)• bosutinib (CML)• ibrutinib (CLL) • obinutuzumab (CLL) • ofatumumab (CLL)• omacetaxine mepesuccinate (CML)• ponatinib (CML, ALL)• radotinib (CML)
• cabozantinib• lenvatinib mesylate• vandetanib
MANY NEW DRUGS FOR THE TREATMENT OF CANCER
Source: IMS Health, MIDAS, Lifecycle, R&D Focus, IMS Institute for Healthcare Informatics, 2015
Many new drugs have been introduced the past 5 years. New drugs and technologies have completely changed the treatment and curing of cancer.
3736
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
At this moment 7,000 new drugs are being developed, of which 1,800 to treat cancer. Many of these medicines are ‘personalised’.
OVER 1.800 ONCOLOGICAL MEDICINES ARE BEING DEVELOPED
Source: IMS Institute for Healthcare Informatics, 2014
38%
1.026
41%
352
38%
102
44%
369
37%
16
62%
59%
62%
56%
63%
biologicals
non-biologicals
Preclinical research
PHASE 1 PHASE 3PHASE 2
Clinical research
Pre-registration & registration
3938
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
Every year approximately 600 applications for new clinical research are submitted, 349 of which by pharmaceutical companies. Most applications are submitted for phase 3 research.
600 APPLICATIONS FOR CLINICAL RESEARCH IN THE NETHERLANDS EVERY YEAR
BULK OF RESEARCH FUNDS SPENT PER CLINICAL TESTING PHASE
Investments in phase 3 clinical research are highest.
Source: EFPIA, 2016
PHASE 1 PHASE 3PHASE 2
Clinical research Usage
Determining dose, safety and effectiveness in patients with the condition con-cerned
Monitoring side effects and longer-term ef-fects in users
Examining how the new medi-cine is tolerated in the body of a limited number of healthy volun-teers
Gaining deeper insight into the effectiveness, advantages and possible side ef-fects in hundreds to thousands of patients who have the condi-tion concerned
Other N/a
349Applications from pharmaceutical companies
233Other applications (public sector, academia)
Source: CCMO, 2016
Preclinical research
PHASE 1 PHASE 3PHASE 2
Clinical research
Registration & reimbursement Usage
21,2%
8,9% 10,7%
28,7%
5,1%
16,6%
8,9%
Examining the effect of new, possibly active substances in the laboratory
Determining dose, safety and effectiveness in patients with the condition con-cerned
Marketing au-thorisation based on submitted research files
Examining how the new medi-cine is tolerated in the body of a limited number of healthy volun-teers
Gaining deeper more insight into the effectiveness, advantages and possible side ef-fects in hundreds to thousands of patients who have the condi-tion concerned
Monitoring side effects and longer-term ef-fects in users
Other
DISTRIBUTION OF INVESTMENTS OVER THE DIFFERENT PHASES OF MEDICINE RESEARCH
119 162 165
5473
9
4140
MEDICINES MONITOR 2017 2017 MEDICINES MONITOR
83 % of the research on new medicines is conducted by pharmaceutical companies.
WHERE DO WE FIND RESEARCH AND DEVELOPMENT (R&D) FOR INNOVATIVE MEDICATION?
MEDICINES OF TOMORROW UNDER DEVELOPMENT
A large number of medicines is under development. Most research is conducted in the field of new cancer medication. In addition, there are many products for metabolic disorders and diseases of the nervous system in the pipeline.
Source: OHE from IMS LifeCycle R&D Focus database, 2015Source: European Medicines Agency, 2014
R&D innovative medication by academical institutes, public and public-private partnerships
R&D innovative medication by large companies
R&D innovative medication by SMEs
17%
27%
56%
28% 5% 3%8% 5% 3%12% 5% 3%5% 3% 3% 3%
Cance
r
Nervo
us sy
stem (e
xclud
ing d
emen
tia)
Met
abolic
diso
rder
s
Skin
cond
itions
Cardiova
scula
r sys
tem
Vacc
ines
Other
Diabet
es
Urogen
ital s
yste
m and se
x horm
ones
Ophtha
lmology
Immun
other
apy
HIV, he
patitis
B/C
Blood dise
ases
3% 2%2% 2%
Bacte
rial in
fectio
ns
Mus
culosk
eletal
diso
rder
s
Demen
tia
Rheum
atoid ar
thrit
is
4%
Respira
tory
syste
m
PHASE 1-3 R&D PER DISEASE AREA
42
MEDICINES MONITOR 2017
Dutch Association Innovative Medicines
P.O.Box 116332502 AP The HagueThe Netherlands
+31 (0)70 - 313 22 22info@innovatievegeneesmiddelen.nlwww.vereniginginnovatievegeneesmiddelen.nl
THE DEVELOPMENT OF A DRUG TAKES 10 YEARS ON AVERAGE
Source: Association Innovative Medicines
200
4YEARS
6YEARS
2YEARS
8YEARS
5YEARS
Patent application
Preclinical research
Clinical research
Registration & reimbursement
Remaining patent period
Supplementary Protection Certificate
(SPC)
Patent expiration
44
OP WEG NAAR EEN NIEUWE GENEESMIDDELENAGENDA